The DOI matches its Crossref record; 23 of the 28 references it cites were found in a registry or an index.
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
Open accessAbstract
Importance: Adjuvant chemotherapy in patients with stage III colon cancer prevents recurrence by eradicating minimal residual disease. However, which patients remain at high risk of recurrence after completing standard adjuvant treatment cannot currently be determined. Postsurgical circulating tumor DNA (ctDNA) analysis can detect minimal residual disease and is associated with recurrence in colorectal cancers. Objective: To determine whether serial postsurgical and postchemotherapy ctDNA analysis could provide a real-time indication of adjuvant therapy efficacy in stage III colon cancer. Design, Setting, and Participants: This multicenter, Australian, population-based cohort biomarker study recruited 100 consecutive patients with newly diagnosed stage III colon cancer planned for 24 weeks of adjuvant chemotherapy from November 1, 2014, through May 31, 2017. Patients with another malignant neoplasm diagnosed within the last 3 years were excluded. Median duration of follow-up was 28.9 months (range, 11.6-46.4 months). Physicians were blinded to ctDNA results. Data were analyzed from December 10, 2018, through June 23, 2019. Exposures: Serial plasma samples were collected after surgery and after chemotherapy. Somatic mutations in individual patients' tumors were identified via massively parallel sequencing of 15 genes commonly mutated in colorectal cancer. Personalized assays were designed to quantify ctDNA. Main Outcomes and Measures: Detection of ctDNA and recurrence-free interval (RFI). Results: After 4 exclusions, 96 eligible patients were eligible; median patient age was 64 years (range, 26-82 years); 49 (51%) were men. At least 1 somatic mutation was identified in the tumor tissue of all 96 evaluable patients. Circulating tumor DNA was detectable in 20 of 96 (21%) postsurgical samples and was associated with inferior recurrence-free survival (hazard ratio [HR], 3.8; 95% CI, 2.4-21.0; P < .001). Circulating tumor DNA was detectable in 15 of 88 (17%) postchemotherapy samples. The estimated 3-year RFI was 30% when ctDNA was detectable after chemotherapy and 77% when ctDNA was undetectable (HR, 6.8; 95% CI, 11.0-157.0; P < .001). Postsurgical ctDNA status remained independently associated with RFI after adjusting for known clinicopathologic risk factors (HR, 7.5; 95% CI, 3.5-16.1; P < .001). Conclusions and Relevance: Results suggest that ctDNA analysis after surgery is a promising prognostic marker in stage III colon cancer. Postchemotherapy ctDNA analysis may define a patient subset that remains at high risk of recurrence despite completing standard adjuvant treatment. This high-risk population presents a unique opportunity to explore additional therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a growing body of data demonstrating numerous clinical applications for ctDNA in adults with solid tumors, ranging from prognostication and evaluation of minimal residual disease (MRD) to detection of targetable alterations.7–12”
From Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study (2026) · cites this paper as [11]
In the citing paper
“A salient example of the well-established relationship between ctDNA burden and disease status in adult solid tumors is the use of ctDNA for MRD detection and monitoring for recurrence in colorectal cancers.10–12”
From Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study (2026) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citationOxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Zaninelli, M., Clingan, P. R., Bridgewater, J. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,694
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
Self-citationLevamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002083220602 · Cited by 2,261
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492
Self-citationMutation tracking in circulating tumor DNA predicts relapse in early breast cancer
García-Murillas, I., Schiavon, G., Weigelt, B., Ng, C. K. Y., Hrebien, S., Cutts, R. J., Cheang, M. C. U., Osin, P., Nerurkar, A. Y., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,174
Detection and quantification of rare mutations with massively parallel sequencing
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W., & Vogelstein, B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105422108 · Cited by 1,144
Self-citationChaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,105
Research works printed but not linked: 1
- Song, 2008, A semiparametric approach for the covariate specific ROC curve with survival outcome., Stat Sin, 947
Cited by
Sorted by citations
Items 201–300 of 690
Yuan, Y., Xiao, W., Xie, W., Cai, P., Wang, Q., Chang, H., Chen, B.-Q., Zhou, W., Zeng, Z., Wu, X., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-07894-6 · Cited by 21
Self-citationPedersen, S. K., Symonds, E. L., Roy, A. C., Cornthwaite, K. J., LaPointe, L. C., & Young, G. P. (2022) · Cancer Medicine · doi:10.1002/cam4.5008 · Cited by 21
The impact of COVID-19 pandemic in the diagnosis and management of colorectal cancer patients
Domper-Arnal, M. J., Hijos, G., & Lanas, Á. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221117636 · Cited by 23
Radiologic T staging of colon cancer: renewed interest for clinical practice
Chang, K. J., Kim, D. H., Lalani, T., Paroder, V., Pickhardt, P. J., Shaish, H. A., & Bates, . D. B. (2023) · Abdominal Radiology · doi:10.1007/s00261-023-03904-2 · Cited by 21
Salvatore, L., Imperatori, M., Arnoldi, E., Carnaghi, C., Cordio, S. S., Cosimelli, M., Cremolini, C., Maiello, E., Martinelli, E., Normanno, N., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-001001 · Cited by 21
Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer
Oki, E., Ando, K., Taniguchi, H., Yoshino, T., & Mori, M. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12503 · Cited by 21
Frydendahl, A., Nors, J., Rasmussen, M. H., Henriksen, T. V., Nesic, M., Reinert, T., Afterman, D., Lauterman, T., Kuzman, M., Gonzalez, S., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114314 · Cited by 21
Kobayashi, S., Nakamura, Y., Hashimoto, T., Bando, H., Oki, E., Karasaki, T., Horinouchi, H., Ozaki, Y., Iwata, H., Kato, T., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02683-0 · Cited by 20
Fan, X., Zhang, J., & Lu, D. (2023) · Medicine · doi:10.1097/md.0000000000032939 · Cited by 20
Crisafulli, G. (2025) · Genes · doi:10.3390/genes16010071 · Cited by 20
Sonoda, H., Yamada, T., Matsuda, A., Ohta, R., Shinji, S., Yokoyama, Y., Takahashi, G., Iwai, T., Takeda, K., Ueda, K., et al. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.05.041 · Cited by 20
Haselmann, V., Hedtke, M., & Neumaier, M. (2022) · Diagnostics · doi:10.3390/diagnostics12030748 · Cited by 20
SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023)
Pericay, C., Montagut, C. O., Reina, J. J., Melián, M., Alcaide, J., Tarazona, N., Ruiz‐Casado, A., González‐Flores, E., Graña, B., & Grávalos, C. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03559-5 · Cited by 22
Clinical Implication of Liquid Biopsy in Colorectal Cancer Patients Treated with Metastasectomy
Lee, S. H., Park, Y. S., Chang, W.-J., Choi, J. Y., Lim, A.-R., Kim, B., Lee, S.-B., Lee, J. W., Kim, S. H., Kim, J., et al. (2021) · Cancers · doi:10.3390/cancers13092231 · Cited by 19
Chen, Y., Mo, S., Wu, M., Li, Y., Chen, X., & Peng, J. (2022) · International Journal of Colorectal Disease · doi:10.1007/s00384-022-04144-4 · Cited by 19
DNA‐Based Materials Inspired by Natural Extracellular DNA
Qin, Z., Wang, C., Zhang, J., Wang, Z., Yu, W. D., Li, Y., Dai, S., Tay, F. R., & Niu, L. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202211669 · Cited by 20
Plumbagin induces ferroptosis in colon cancer cells by regulating p53-related SLC7A11 expression
Wang, B., Kong, W., Lv, L., & Wang, Z. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28364 · Cited by 19
Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review
Ashouri, K., Wong, A., Mittal, P., Torres‐Gonzalez, L., Lo, J. H., Soni, S., Algaze, S. D., Khoukaz, T., Zhang, W., Yang, Y., et al. (2024) · Cancers · doi:10.3390/cancers16162796 · Cited by 20
Housein, Z., Kareem, T. S., & Salihi, A. B. (2021) · Scientific Reports · doi:10.1038/s41598-021-82244-x · Cited by 19
Hoang, T., Choi, M. K., Oh, J. H., & Kim, J. (2025) · International Journal of Cancer · doi:10.1002/ijc.35442 · Cited by 19
Li, X., Jonnagaddala, J., Yang, S., Zhang, H., & Xu, S. X. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03976-5 · Cited by 18
Colorectal liver metastases: state-of-the-art management and surgical approaches
Newhook, T. E., & Vauthey, J. (2022) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-022-02496-7 · Cited by 18
Gögenur, M., Hadi, N. A.-H., Qvortrup, C., Andersen, C. L., & Gögenür, I. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12366-7 · Cited by 18
Liu, P., Wang, X., Dun, A., Li, Y., Li, H., Wang, L., Zhang, Y., Li, C., Zhang, J., Zhang, X., et al. (2023) · Engineering · doi:10.1016/j.eng.2023.02.008 · Cited by 18
Potential biomarkers for immunotherapy in non-small-cell lung cancer
Wang, X., Qiao, Z.-Y., Aramini, B., Lin, D. X., Li, X., & Fan, J. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10074-y · Cited by 18
Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment
Yao, S., Han, Y., Yang, M., Jin, K., & Lan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292861 · Cited by 19
Shu, T., Liang, Y., Zhang, S., Sun, T., Gao, Y., Guo, C., Li, Z., Gao, M., Zhang, N., Song, N., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.11.002 · Cited by 18
The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal
Dizdarevic, E., Hansen, T. F., & Jakobsen, A. K. M. (2022) · Cancers · doi:10.3390/cancers14092252 · Cited by 18
Honoré, N., Laliotis, G., Aushev, V. N., Velichko, S., Palsuledesai, C. C., Dahou, H., van Marcke, C., Galot, R., Liu, M., & Machiels, J.-P. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104534 · Cited by 17
Gao, Z., Huang, D., Chen, H., Yang, Y., An, K., Ding, C., Yuan, Z., Zhai, Z., Niu, P., Gao, Q., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-023-03884-3 · Cited by 18
Self-citationThe Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer
de Abreu, A. R., de Beeck, K. O., Laurent‐Puig, P., Taly, V., & Benhaïm, L. (2023) · Cancers · doi:10.3390/cancers15041284 · Cited by 17
Current and emerging applications of liquid biopsy in pan-cancer
Wang, W., He, Y., Yang, F., & Chen, K. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101720 · Cited by 17
Role of Circulating Tumor DNA Among Patients with Colorectal Peritoneal Metastases
Baumgartner, J. M., & Botta, G. P. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-023-00959-8 · Cited by 18
Fan, W., Xia, Z., Chen, R., Lin, D., Li, F., Zheng, Y., Luo, J., Xiong, Y., Yu, P., Gao, W., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231220607 · Cited by 19
Self-citationYaegashi, M., Iwaya, T., Sasaki, N., Fujita, M., Ju, Z., Siwak, D. R., Hachiya, T., Sato, K. A., Endo, F., Kimura, T., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01266-4 · Cited by 17
A Review of Circulating Tumor DNA in the Diagnosis and Monitoring of Esophageal Cancer
Min, J., Zhou, H., Jiang, S., & Yu, H. (2021) · Medical Science Monitor · doi:10.12659/msm.934106 · Cited by 17
Predictive Biomarkers in Cancer Immunotherapy: A Narrative Review Across Selected Solid Tumors
Puntambekar, M., Shery, N., Parokkaran, I. P., & Al-Hamas, M. (2025) · Cureus · doi:10.7759/cureus.88647 · Cited by 17
Sato, S., Nakamura, Y., Oki, E., & Yoshino, T. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.12.001 · Cited by 16
Ciardiello, D., Blauensteiner, B., Matrone, N., Belli, V., Mohr, T. T., Vitiello, P. P., Martini, G., Poliero, L., Cardone, C., Napolitano, S., et al. (2021) · Medical Oncology · doi:10.1007/s12032-021-01464-3 · Cited by 16
A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study
Procaccio, L., Bergamo, F., Daniel, F., Rasola, C., Munari, G., Biason, P., Crucitta, S., Barsotti, G., Zanella, G., Angerilli, V., et al. (2021) · Cancers · doi:10.3390/cancers13205128 · Cited by 16
Wada, Y., Shimada, M., Morine, Y., Ikemoto, T., Saito, Y., Zhu, Z., Wang, X., Etxart, A., Park, Y., Bujanda, L., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00015 · Cited by 16
Kasi, P. M. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00298 · Cited by 16
Henriksen, T. V., Reinert, T., Rasmussen, M. H., Demuth, C., Løve, U. S., Madsen, A. H., Gotschalck, K. A., Iversen, L. H., & Andersen, C. L. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13294 · Cited by 16
Vojjala, N., Gibatova, V., Shah, R. N., Singal, S., Prabhu, R. R., Krishnamoorthy, G., Riggins, K. S., & Moka, N. (2025) · Cancers · doi:10.3390/cancers17152520 · Cited by 15
Circulating DNA changes are predictive of disease progression after transarterial chemoembolization
Sefrioui, D., Verdier, V., Savoye‐Collet, C., Beaussire, L., Ghomadi, S., Gangloff, A., Goria, O., Riachi, G., Montialoux, H., Schwarz, L., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33829 · Cited by 15
Overview of the role of liquid biopsy in cancer management
Assi, T., Khoury, R., Ibrahim, R., Baz, M., Ibrahim, T., & Cesne, A. L. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101702 · Cited by 15
Soueidy, C., Zaanan, A., Gelli, M., Moati, É., Gallois, C., Taly, V., Laurent‐Puig, P., Benhaïm, L., & Taı̈eb, J. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100068 · Cited by 15
Defining colon cancer biomarkers by using deep learning
Specogna, A. V., & Sinicrope, F. A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30034-9 · Cited by 15
Wo, J. Y.-L., Clark, J. W., Eyler, C. E., Mino-Kenudson, M. A., Klempner, S. J., Allen, J. N., Keane, F. K., Parikh, A. R., Roeland, E. J., Drapek, L. C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0331 · Cited by 16
Smith, H. G., Skovgaards, D. M., Chiranth, D., & Schlesinger, N. H. (2022) · Colorectal Disease · doi:10.1111/codi.16121 · Cited by 15
Mi, J., Han, X., Wang, R., Ma, R.-J., & Zhao, D. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13842 · Cited by 15
Liu, W., Jin, K., Zhang, M.-H., Bao, Q., Liu, M., Xu, D., Wang, K., & Xing, B. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13362-1 · Cited by 15
State of the Science and Future Directions for Liquid Biopsies in Drug Development
Narayan, P., Ghosh, S., Philip, R., Barrett, J. C., Mccormack, R. T., Odegaard, J. I., Oxnard, G. R., Pracht, L. J., Williams, P. M., Kelloff, G. J., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0246 · Cited by 15
Redefining Colorectal Cancer by Tumor Biology
Salem, M. E., Puccini, A., & Tie, J. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279867 · Cited by 14
Self-citationKatsimperis, S. N., Tzelves, L. I., Feretzakis, G., Bellos, T. C., Tsikopoulos, I., Κωστακόπουλος, Ν., & Skolarikos, A. (2025) · Cancers · doi:10.3390/cancers17121908 · Cited by 14
Udagawa, S., Ooki, A., Shinozaki, E., Fukuda, K., Yamaguchi, K., & Osumi, H. (2023) · Cancers · doi:10.3390/cancers15051473 · Cited by 14
Bikhchandani, M., Amersi, F. F., Hendifar, A. E., Gangi, A., Osipov, A., Zaghiyan, K. N., Atkins, K. M., Cho, M. T., Aguirre, F. P., Hazelett, D. J., et al. (2023) · Genes · doi:10.3390/genes14051054 · Cited by 14
Circulating tumor DNA (ctDNA)-based minimal residual disease in non-small cell lung cancer
Tang, L.-B., Li, R., Wen, H., Zhou, Q. H., & Xu, C. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2023.04.001 · Cited by 16
Qi, Z., Li, Y., Wang, Z., Tan, X., Zhou, Y., Li, Q., Zhao, W., Zheng, X. M., Yao, J., Li, F., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6286 · Cited by 14
Allan, Z., Liu, D. S., Lee, M., Tie, J., & Clemons, N. J. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvad188 · Cited by 14
Self-citationYang, H., Xiao, X., Zeng, L., Zeng, H., Zheng, Y., Wang, J., Li, G., Dai, W., He, Y., Wang, S., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04675-6 · Cited by 14
Zhang, Z.-T., Xiao, W., Li, L., Wu, X.-J., Wang, Q., Chang, H., Tian, X., Wu, J., Lin, J., Zhang, R.-X., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102836 · Cited by 14
Self-citationDiergaarde, B. B., Young, G., Hall, D. W., Mazloom, A. R., Costa, G. L., Subramaniam, S., Palomares, M. R., Garces, J., Baehner, F. L., Schoen, R. E., et al. (2025) · Journal of Surgical Oncology · doi:10.1002/jso.27989 · Cited by 15
Precision medicine for adjuvant chemotherapy of resected colorectal cancer
Miyamoto, Y., Hiyoshi, Y., Sawayama, H., Tokunaga, R., & Baba, H. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12397 · Cited by 14
Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy
Bañobre, J. R., & Goel, A. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.02.008 · Cited by 15
SSR4 as a prognostic biomarker and related with immune infiltration cells in colon adenocarcinoma
He, W., Wang, B., He, J., Zhao, Y., & Zhao, W. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2019015 · Cited by 15
Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer
Gong, J., Aguirre, F. P., Hazelett, D. J., Alvarez, R., Zhou, L., Hendifar, A. E., Osipov, A., Zaghiyan, K. N., Cho, M. T., Gangi, A., et al. (2022) · Molecular and Clinical Oncology · doi:10.3892/mco.2022.2533 · Cited by 13
Jiang, H., Huang, F., Yang, Y., Chen, X., Shen, M., Zhang, C., Pan, B., Wang, B., & Guo, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1153685 · Cited by 13
Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis
Mittal, A., Moltó, C., Tamimi, F., Iorio, M. R. D., Al-Showbaki, L., Cescon, D. W., & Amir, E. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad040 · Cited by 13
Kampel, L., Feldstein, S., Tsuriel, S., Hannes, V., Neiderman, N. N. C., Horowitz, G., Warshavsky, A., Leider–Trejo, L., Hershkovitz, D., & Muhanna, N. (2023) · Biomolecules · doi:10.3390/biom13091418 · Cited by 13
Clinical Applications of Circulating Tumor DNA Profiling in GI Cancers
Battaglin, F., & Lenz, H. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00167 · Cited by 13
Circulating Tumor DNA Testing in Curatively Resected Colorectal Cancer and Salvage Resection
Ji, J., Wang, C., Goel, A., Melstrom, K. A., Zerhouni, Y. A., Lai, L. L., Melstrom, L. G., Raoof, M., Fong, Y., Kaiser, A. M., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.52661 · Cited by 13
Ozawa, T., Matsuda, K., Ishihara, S., Fukushima, Y., Shimada, R., Hayama, T., Nozawa, K., & Hashiguchi, Y. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26497 · Cited by 14
Hedtke, M., Rejas, R. P., Froelich, M. F., Ast, V., Duda, A., Mirbach, L., Costina, V., Martens, U. M., Hofheinz, R., Neumaier, M., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13156 · Cited by 13
Kolenčík, D., Narayan, S., Thiele, J.-A., McKinley, D., Gerdtsson, A. S., Welter, L. M., Hošek, P., Ostašov, P., Vyčítal, O., Brůha, J., et al. (2022) · Cancers · doi:10.3390/cancers14030642 · Cited by 13
Shah, U. J., Alsulimani, A., Ahmad, F., Mathkor, D. M., Alsaieedi, A., Harakeh, S., Nasiruddin, M., & Haque, S. (2022) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2022.2108994 · Cited by 14
Li, Y., & Niu, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-20040-x · Cited by 13
Murakami, N., Watanabe, M., Uno, T., Sekii, S., Tsujino, K., Kasamatsu, T., Machitori, Y., Aoshika, T., Kato, S., Hirowatari, H., et al. (2023) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2023.34.e24 · Cited by 13
Nomura, M., Miyake, Y., Inoue, A., Yokoyama, Y., Noda, N., Kouda, S., Hata, T., Ogino, T., Miyoshi, N., Takahashi, H., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11010203 · Cited by 13
ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care?
Puccini, A., Martelli, V., Pastorino, A., Sciallero, S., & Sobrero, A. F. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01048-x · Cited by 13
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial
Boehnke, A., Melero, I., Tanos, T., Calvo, E., Qvortrup, C., van Dongen, M., Baraibar, I., Beom, S.-H., Thistlethwaite, F. C., García, M. A. F., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04380-z · Cited by 12
Metachronous colorectal cancer metastasis: Who, what, when and what to do about it
Cohen, R., & Platell, C. F. E. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27400 · Cited by 12
Minimal residual disease in solid tumors: an overview
Ma, Y., Gan, J., Bai, Y., Cao, D., & Jiao, Y. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1018-6 · Cited by 13
Guo, N., Zhou, Q., Chen, X., Zeng, B., Wu, S., Zeng, H., & Sun, F. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.01.003 · Cited by 12
Hakami, Z. H. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155216 · Cited by 12
Wang, Z.-Z., Liu, Y., Wang, K., & Ma, L. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03554-8 · Cited by 12
Yang, W., Zou, J., Li, Y., Liu, R., Yan, Z., Chen, S., Zhao, X., Guo, W., Huang, M., Li, W., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.830816 · Cited by 12
Colorectal Cancer Surveillance With Circulating Tumor DNA Assay
Venook, A. P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.1100 · Cited by 12
Identification and validation of a 17-gene signature to improve the survival prediction of gliomas
Tong, S., Xia, M., Xu, Y., Sun, Q., Ye, L., Cai, J., Ye, Z., & Tian, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1000396 · Cited by 12
Koulouris, A., Tsagkaris, C., Messaritakis, I., Gouvas, N., Sfakianaki, M., Trypaki, M., Spyrou, V., Christodoulakis, M. S., Athanasakis, E., Xynos, E., et al. (2021) · Cancers · doi:10.3390/cancers13143522 · Cited by 12
The current state of molecular profiling in gastrointestinal malignancies
Mukherji, R., Yin, C., Hameed, R., Alqahtani, A. J., Kulasekaran, M., He, A. R., Weinberg, B. A., Marshall, J. L., Hartley, M. L., & Noel, M. S. (2022) · Biology Direct · doi:10.1186/s13062-022-00322-0 · Cited by 13
Adjuvant chemotherapy in colon cancer: state of the art and future perspectives
Iveson, T. J. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000640 · Cited by 12
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib
Zhang, G. Q., Meyerhardt, J. A., Shi, Q., Twombly, T. S., Pederson, L., Ma, C., Väyrynen, J. P., Zhao, M. M., Takashima, Y., Shergill, A. P., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.5144 · Cited by 14
Lin, P., Tsai, L., Lo, C., Kuo, S., Ni, C.-C., Yu, C.-H., & Huang, C. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0234 · Cited by 11
Sinicrope, F. A., Segovia, D., Sharma, N., Alberts, S. R., Hardin, A. I., Rich, T. A., & Shi, Q. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02086 · Cited by 14
Stasik, S., Mende, M., Schuster, C., Mahler, S., Aust, D., Tannapfel, A., Reinacher‐Schick, A., Baretton, G. B., Krippendorf, C., Bornhäuser, M., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.811291 · Cited by 11
Chen, Z., Ji, X., Xu, Y., Fong, W. P., Liu, X., Liang, J., Tan, Q., Wen, L., Cai, Y., Wang, D., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241230752 · Cited by 11
A standing platform for cancer drug development using ctDNA-based evidence of recurrence
Medford, A. J., Carmeli, A. B., Ritchie, A., Wagle, N., Garraway, L. A., Lander, E. S., & Parikh, A. R. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00742-2 · Cited by 12
Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: A Review of Methods and Applications
Dubrovsky, G., Ross, A., Jalali, P., & Lotze, M. T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011013 · Cited by 11
Negoi, I. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i18.106670 · Cited by 11
Metadata
- Authors
- Tie, J., Cohen, J. D., Wang, Y., Christie, M., Simons, K., Lee, M., Wong, R., Kosmider, S., Ananda, S., McKendrick, J., Lee, B., Cho, J. H., Faragher, I., Jones, I. T., Ptak, J., Schaeffer, M. J., Silliman, N., Dobbyn, L., Li, L., Tomasetti, C., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., & Gibbs, P.
- Affiliations
- The University of Melbourne (AU)
- Johns Hopkins University (US)
- The Royal Melbourne Hospital (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Western Health (AU)
- Eastern Health (AU)
- Division of Biostatistics & Bioinformatics, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Corresponding author
- Tie, Jeanne
- ORCID
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-12-01
- Volume
- 5
- Issue
- 12
- Pages
- 1710
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC6802034
- OpenAlex
- W2980567593
- Cited by
- 668
- References
- 28
- Citations by year
- 2026: 76 · 2025: 91 · 2024: 104 · 2023: 124 · 2022: 107 · 2021: 102 · 2020: 57 · 2019: 6
- FWCI
- 21.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P50CA062924)
- National Institute of General Medical Sciences (T32GM136577)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- circulating tumor DNA, stage III colon cancer, adjuvant chemotherapy, recurrence risk, minimal residual disease, recurrence-free interval, somatic mutations, liquid biopsy, predictive biomarkers, treatment response monitoring, recurrent colorectal cancer, recurrence-free survival, prognostic factors
- MeSH terms
- Circulating Tumor DNA, Adult, Aged, Aged, 80 and over, Australia, Colonic Neoplasms, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Risk Factors, Biomarkers, Tumor, Treatment Outcome, Chemotherapy, Adjuvant, Neoplasm, Residual, Disease-Free Survival, Precision Medicine, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
